Ask Warren

NGeneBio

354200 · KOSDAQ · ₩354200 · 엔젠바이오

₩665▼ ₩16 (2.35%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
SellBuy

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

With these assumptions the model gives no positive value.

Enterprise value
−₩368B
Equity value
−₩400B
WACC
4.9%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model gives no positive value at these assumptions. What we can see:

  • To match today's price of ₩665, the model needs an operating margin of 3.0% every year (it uses −20.0%).
  • Margins ranged from −308.6% to −39.0% over the last 5 years, so this is a cyclical business. The model uses the average; the price may be set by where the cycle is now. Try the margin fade option.
  • In the projection, spending on equipment, software and working capital takes most or all of the after-tax operating profit, so free cash flow is thin. Companies that invest heavily often look like this until spending slows.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
—
Base
—
Bull
—

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (−20.0%).

Revenue growth

  • 24.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (24.5% a year, annual reports), fading to 3% by year 5.

  • 19.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (24.5% a year, annual reports), fading to 3% by year 5.

  • 13.7%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (24.5% a year, annual reports), fading to 3% by year 5.

  • 8.4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (24.5% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (24.5% a year, annual reports), fading to 3% by year 5.

Business

  • -20%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 6.4%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 8%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • -10%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta -0.73, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩42B
Net debt (borrowings and leases − cash and deposits)
₩32B
Shares
16,086,583
Share price
₩665
Market cap
₩11B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩4.4B₩5.7B₩21B₩52B₩62B₩70B₩76B₩79B
Growth−60.5%30.8%273.2%24.5%19.1%13.7%8.4%3.0%
EBIT−₩13B−₩16B−₩8.3B−₩10B−₩12B−₩14B−₩15B−₩16B
EBIT margin−308.6%−282.5%−39.0%−20.0%−20.0%−20.0%−20.0%−20.0%
After-tax EBIT−₩9.7B−₩12B−₩6B−₩7.5B−₩9B−₩10B−₩11B−₩11B
+ Depreciation———₩3.3B₩4B₩4.5B₩4.9B₩5B
− Capital spending₩828M₩239M₩136M₩4.2B₩5B₩5.6B₩6.1B₩6.3B
− Working capital−₩5.1B₩6.6B₩4.6B−₩1B−₩994M−₩849M−₩592M−₩229M
Free cash flow———−₩7.4B−₩9B−₩10B−₩12B−₩12B
Discount factor———0.9530.9090.8660.8260.787
Present value———−₩7B−₩8.2B−₩9.1B−₩9.7B−₩9.8B

Terminal value −₩412B, worth −₩325B today: 88% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩1,190 a share)Now 0.56×₩2,3711.99×₩11,7949.91×₩14,84612.5×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
3.9%—————
4.4%—————
4.9%—————
5.4%—————
5.9%—————

Now (TTM)

Market cap
₩11B
Enterprise value
₩42B
P/E
—
P/B
0.6×
P/S
0.3×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩3,583₩4,029₩12,927₩21,575₩37,664
Market cap₩58B₩65B₩208B₩347B₩606B
P/E—————
P/B2.5×3.8×12.8×13.7×17.8×
P/S2.7×11.4×47.8×31.5×84.6×
EV/EBITDA—————
Dividend yield0.0%————

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
NGeneBio—0.6×0.3×—0.0%
S-123.7×2.1×1.3×—0.0%
Cheil Worldwide9.7×1.3×0.5×—6.6%
Doosan Tesna59.6×4.5×6.2×—0.2%
Lotte Tour Development16.0×2.2×1.2×—0.0%
Soulbrain Holdings1.3×0.4×1.3×—1.3%
Innocean Worldwide5.5×0.6×0.3×—6.7%
Similar companies (median)12.9×1.7×1.2×—0.7%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: NGeneBio / 엔젠바이오 / 354200 / KRX:354200

Source: KRX statistical information